SecSonar.com

Telix Pharmaceuticals Limited (TLX)

Telix Pharmaceuticals Limited at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Telix Pharmaceuticals Limited (TLX) is a Biotechnology company based in AU with a market capitalization of $3.2B. Revenue grew 53.9% year-over-year and free cash flow was negative at -$57.5M. This page tracks TLX's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

AU · 1.12K employees · IPO Nov 14, 2024

Valuation

Valuation & price

$10.56 · as of May 17, 2026 · -37.6% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

5.15

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$16.92$11.67$6.41Jul 25Dec 25Jul 26Jul 7, 25$15.49Jul 9, 25$16.92Jul 11, 25$15.97Jul 15, 25$15.53Jul 17, 25$16.14Jul 21, 25$16.50Jul 23, 25$14.58Jul 25, 25$14.20Jul 29, 25$13.49Jul 31, 25$13.59Aug 4, 25$13.32Aug 6, 25$11.97Aug 11, 25$10.89Aug 13, 25$11.18Aug 15, 25$11.54Aug 19, 25$11.30Aug 21, 25$12.09Aug 25, 25$12.20Aug 27, 25$12.10Aug 29, 25$9.55Sep 3, 25$9.36Sep 5, 25$9.06Sep 9, 25$9.29Sep 11, 25$9.32Sep 16, 25$9.42Sep 18, 25$9.16Sep 22, 25$10.05Sep 24, 25$10.21Sep 26, 25$9.98Sep 30, 25$9.57Oct 2, 25$10.22Oct 6, 25$10.18Oct 8, 25$10.24Oct 10, 25$9.57Oct 14, 25$10.04Oct 16, 25$10.86Oct 21, 25$10.92Oct 23, 25$10.88Oct 27, 25$10.95Oct 29, 25$10.63Oct 31, 25$10.66Nov 4, 25$10.28Nov 6, 25$9.88Nov 10, 25$10.08Nov 12, 25$9.81Nov 14, 25$9.34Nov 18, 25$9.18Nov 20, 25$8.77Nov 25, 25$9.64Nov 28, 25$9.95Dec 2, 25$9.48Dec 4, 25$9.78Dec 8, 25$9.67Dec 10, 25$9.92Dec 12, 25$9.03Dec 16, 25$8.34Dec 18, 25$7.81Dec 22, 25$8.05Dec 24, 25$8.10Dec 29, 25$7.84Jan 2, 26$7.62Jan 6, 26$7.46Jan 8, 26$7.63Jan 12, 26$7.55Jan 14, 26$7.62Jan 16, 26$7.76Jan 21, 26$7.31Jan 23, 26$7.61Jan 27, 26$8.36Jan 29, 26$7.75Feb 2, 26$7.43Feb 4, 26$7.13Feb 9, 26$7.08Feb 11, 26$6.93Feb 13, 26$6.54Feb 18, 26$6.41Feb 20, 26$7.69Feb 24, 26$6.56Feb 26, 26$7.52Mar 2, 26$7.05Mar 4, 26$6.87Mar 6, 26$7.52Mar 10, 26$7.90Mar 12, 26$7.89Mar 17, 26$8.32Mar 19, 26$8.57Mar 23, 26$9.13Mar 25, 26$8.90Mar 27, 26$9.20Mar 31, 26$9.57Apr 2, 26$9.13Apr 7, 26$9.63Apr 9, 26$9.80Apr 13, 26$11.24Apr 15, 26$10.66Apr 17, 26$10.74Apr 22, 26$10.33Apr 24, 26$10.56Apr 28, 26$10.44Apr 30, 26$11.00May 4, 26$11.15May 6, 26$11.11May 8, 26$10.68May 12, 26$10.39May 14, 26$10.86May 18, 26$10.28May 20, 26$10.28May 22, 26$9.47May 28, 26$9.53Jun 1, 26$9.42Jun 3, 26$8.77Jun 5, 26$9.30Jun 9, 26$9.41Jun 11, 26$9.45Jun 15, 26$9.54Jun 17, 26$9.94Jun 22, 26$10.00Jun 24, 26$10.90Jun 26, 26$10.66Jul 2, 26$11.87
$6.4152-week range$16.92
Loading valuation history…

Fundamentals

Key fundamentals

$3.2B

Market cap

53.9%

Revenue growth (YoY)

53.1%

Gross margin

-$57.5M

Free cash flow (USD)

$571.9M

Net debt

2.0%

Share dilution

1/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$0.00FY 2017$0.00FY 2018$195.1KFY 2019$3.5MFY 2020$5.2MFY 2021$7.6MFY 2022$160.1MFY 2023$502.5MFY 2024$783.2MFY 2025$1.2B
$0$1.2B

Free cash flow by year

2016 → 2025

FY 2016$0.00FY 2017$-6.0MFY 2018$-20.7MFY 2019$-23.7MFY 2020$1.7MFY 2021$-60.7MFY 2022$-71.0MFY 2023$14.2MFY 2024$28.7MFY 2025$-82.8M
$0-$82.8M

Gross margin by year

2021 → 2025

FY 2021-391.9%FY 202218.3%FY 202362.6%FY 202465.1%FY 202553.1%
-391.9%53.1%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

1

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 6-K filed May 21, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 6-K filingFDA Alignment AnnouncementJul 2, 2026Filing
  • Annual reportAnnual Report FiledMay 21, 2026Filing
  • Insider buyInsider Buy $997KBehrenbruch Christian · Director, MD & Group CEO · $996.7KMay 6, 2026Filing
  • 6-K filingConvertible Bonds SettlementApr 23, 2026Filing
  • 6-K filingAGM NoticeApr 21, 2026Filing
  • 6-K filingConvertible Bond Cleansing NoticeApr 20, 2026Filing
  • Quarterly reportQuarterly Report FiledApr 14, 2026Filing
  • 6-K filingConvertible Bonds OfferingApr 14, 2026Filing
  • 6-K filingRadiopharma CollaborationApr 13, 2026Filing
  • 6-K filingFDA NDA AcceptanceApr 10, 2026Filing

Questions

Frequently asked questions

What is Telix Pharmaceuticals Limited's market cap?

Telix Pharmaceuticals Limited (TLX) has a market capitalization of $3.2B.

What is TLX's P/E ratio?

A meaningful P/E ratio is not available for TLX — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is TLX's price-to-book (P/B) ratio?

TLX trades at 5.15 times book value per share.

Are insiders buying TLX stock?

Yes — SEC Form 4 filings show 1 open-market insider buy and 0 sells at Telix Pharmaceuticals Limited in the last 90 days.

Same arena

Related companies in Biotechnology

DNLI

Denali Therapeutics Inc.

$3.4B

BEAM

Beam Therapeutics Inc.

$3.4B

KNSA

Kiniksa Pharmaceuticals, Ltd.

$3.7B

ARQT

Arcutis Biotherapeutics, Inc.

$2.7B

ACAD

ACADIA Pharmaceuticals Inc.

$3.7B

CRNX

Crinetics Pharmaceuticals, Inc.

$3.7B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.